news roundup

PAREXEL and Datavant Partner to Deliver Data and Real-World Evidence Analytics

PAREXEL and Datavant, Inc., a healthcare technology company focused on enabling the secure de-identification and linking of healthcare datasets, announced they are partnering toward clinical study design and operations, as well as the generation of RWE. The collaboration hopes to enable the linking of healthcare data from a variety of real-world and clinical study data.

Aptus Clinical and the Cell and Gene Therapy Catapult Announce Their Clinical Service Partnership

CRO Aptus Clinical has been appointed as a supplier for clinical services by the Cell and Gene Therapy Catapult (CGTC). As an early-phase CRO, its role is to support development and delivery of advanced therapy studies in the UK and Europe. Through this partnership, Aptus Clinical will primarily provide dedicated site set-up and monitoring of investigational sites for the CGTC's collaborators.

Clinerion and S4 Research Partner

Clinerion and S4 Research announce a partnership to expand the global network of hospitals on the Clinerion's Patient Network Explorer platform into India. S4 Research's wide network in India and clinical trials experience, will support Clinerion in the expansion of its global network of partner hospitals in India.

Global CRO Signs TrialOne Agreement With OmniComm Systems

A global CRO has signed a new agreement extending its relationship with OmniComm Systems, Inc., a provider of clinical data management technology, for another seven years. Under the terms of the agreement, the CRO will use OmniComm's TrialOne eClinical solution in order to automate early phase studies at one of its U.S.-based clinical research units.

Articles

RBM: Barriers to Adoption

The results of a 2018 survey of sponsor, CRO, and technology companies.

Improved Understanding of Psoriasis Buoys Treatment Hopes for Patients

Advances in our understanding of the genetic, immunological, and environmental factors that contribute to the pathogenesis of psoriasis have led to the development of very effective precision therapies that alleviate patient morbidity and improve quality of life, especially for patients with moderate to severe disease.

Ask the editor

Lisa Henderson
Editor in Chief
Lisa.Henderson@ubm.com